HHS peptide policy: what changed for BPC-157 and five others

01

What HHS actually did

This is enforcement discretion, not approval. The six peptides stay unapproved, and they are not on the 503A bulks list, which FDA is still developing through rulemaking.

HHS says the policy runs until a final rule decides whether each peptide goes on that list. It may revisit the policy sooner if a safety signal or product quality issue arises.

The Federal Register notice calls the document a draft that “does not establish any rights for any person and is not binding on HHS or the public.” Written comments are open for two weeks after publication, which is until about November 13, 2026.

Sources: [1] HHS · 503A peptide enforcement discretion policy · 2026 · [2] Federal Register · 2026-22192 · October 30, 2026

02

What a compounder has to do

The policy applies only when all of its conditions are met. The main ones:

• Compound against a valid, patient-specific prescription.
• Use a bulk ingredient whose original manufacturer is registered with FDA and follows current good manufacturing practice, with the facility’s location on the certificate of analysis.
• Hold a certificate of analysis showing identity, purity, potency and the absence of harmful contaminants such as endotoxins, heavy metals and microbes.
• Make single-ingredient products only. Each product may hold one listed peptide, so blends fall outside the policy.
• Label the product “This is a compounded drug product. Not for resale.”
• Report products compounded, serious adverse events and quality problems to FDA and the states involved.
• Co-package or use no drug delivery device more complex than an FDA 510(k)-cleared syringe.

Sources: [1] HHS · 503A peptide enforcement discretion policy · 2026

03

The forms the policy names for each peptide

Appendix B of the policy limits each peptide to a specific form and route for compounding:

• BPC-157 acetate: subcutaneous, intramuscular, oral and topical.
• TB-500 acetate: subcutaneous or intramuscular injectable.
• MOTS-c acetate: subcutaneous or intramuscular injectable.
• Epitalon acetate: subcutaneous or intramuscular injectable, dispensed in intermittent courses.
• Semax free base: intranasal.
• KPV acetate: topical and oral.

These are limits on what a compounder may make under the policy. They are not instructions for any product, and they say nothing about research material.

Sources: [1] HHS · 503A peptide enforcement discretion policy · 2026

04

What FDA’s reviewers and the advisory committee said

Appendix B records a split. For each of the six, FDA’s Center for Drug Evaluation and Research recommended against listing the peptide, and the Pharmacy Compounding Advisory Committee voted in favor.

HHS gives three kinds of reason for going ahead: newer lot certificates that report results the Center had found missing, use that is now documented, and the policy’s own conditions or its reading of the safety record. These are HHS’s reasons for an interim policy, not an FDA finding that any of the six is safe or effective.

Sources: [1] HHS · 503A peptide enforcement discretion policy · 2026

05

What it does not change

• No FDA approval. In HHS’s words, compounded drugs are not FDA-approved, “which means FDA does not review their safety, effectiveness, or quality before they are marketed.”
• Other peptides are not covered. Only the six in Appendix A are named.
• Research-use products are outside it. The policy addresses compounding for a named patient. HHS says it “will discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients.”

Sources: [1] HHS · 503A peptide enforcement discretion policy · 2026

06

Where this leaves research-use peptides

Prism Labs is not a compounding pharmacy or an outsourcing facility, and this policy does not cover what we sell. Our vials are sold for laboratory research use only, and that has not changed. They are not compounded drugs and are not for human or veterinary use.

For a patient, the route the policy describes is a prescription filled by a licensed compounder.

More on the label itself: what research peptides are and what RUO means.

Sources: [1] HHS · 503A peptide enforcement discretion policy · 2026